Infantile Hemangioma

• Infantile Hemangioma is the most common benign vascular tumor of infancy, appearing shortly after birth.
• These lesions typically undergo a rapid growth phase followed by a slower, natural regression.
• Diagnosis is primarily clinical, based on the characteristic appearance and growth pattern.
• Treatment options vary from watchful waiting to medication, depending on the hemangioma’s size, location, and potential for complications.

What is Infantile Hemangioma?

Infantile Hemangioma refers to a type of benign (non-cancerous) vascular tumor that is typically present at or shortly after birth, becoming visible within the first few weeks of life. It is the most common tumor of infancy, affecting approximately 4-5% of infants, with a higher incidence in premature infants, females, and those of Caucasian descent, according to the American Academy of Pediatrics. These hemangiomas are characterized by a unique life cycle involving a proliferative phase, where they grow rapidly, followed by an involution (regression) phase, where they gradually shrink and fade over several years.

While often superficial and appearing as red patches or raised lesions on the skin, infantile hemangiomas can also be deep, appearing as bluish lumps, or mixed, combining both superficial and deep components. Their appearance and growth pattern are key to understanding what is Infantile Hemangioma and distinguishing it from other birthmarks or vascular anomalies.

Recognizing Infantile Hemangioma: Symptoms and Diagnosis

Recognizing the signs of an infantile hemangioma early is important for monitoring its progression. The primary Infantile hemangioma symptoms and causes involve its characteristic appearance and growth pattern. Typically, a small red mark or pale area may be present at birth, which then rapidly grows during the first 5-7 months of life. This proliferative phase can be quite dramatic, with the lesion becoming bright red and raised (strawberry hemangioma) if superficial, or a bluish, soft mass if deep. While the exact cause is unknown, it is believed to involve abnormal proliferation of endothelial cells, which line blood vessels.

Diagnosing infantile hemangioma is primarily a clinical process, meaning it is based on a physical examination and the characteristic history of the lesion’s appearance and growth. A healthcare provider will observe the lesion’s color, texture, size, and location. In most cases, no further tests are needed. However, if the hemangioma is large, rapidly growing, located in a sensitive area (e.g., near the eye, airway, or diaper area), or if there’s concern about internal involvement, imaging studies may be recommended. These can include:

• Ultrasound: Often the first-line imaging for superficial or subcutaneous lesions, providing information on size and depth.
• MRI (Magnetic Resonance Imaging): Used for larger or deeper hemangiomas, especially those potentially affecting internal organs or vital structures, to assess their full extent.

These diagnostic tools help confirm the diagnosis and rule out other vascular anomalies, ensuring appropriate management.

Infantile Hemangioma Treatment Options

The approach to Infantile hemangioma treatment depends on several factors, including the hemangioma’s size, location, growth rate, and whether it is causing complications or functional impairment. Many infantile hemangiomas are small, do not cause problems, and will eventually resolve on their own, requiring only watchful waiting and regular monitoring by a pediatrician.

For hemangiomas that are large, rapidly growing, or located in areas that could impair vision, breathing, feeding, or cause ulceration and pain, active treatment may be necessary. The current first-line treatment is oral propranolol, a beta-blocker medication. Propranolol has revolutionized treatment by effectively stopping growth and accelerating the involution process. It works by constricting blood vessels, reducing blood flow to the hemangioma, and inhibiting the growth of new blood vessels. Other treatment options may include:

• Topical beta-blockers (e.g., timolol gel): Used for small, superficial hemangiomas.
• Corticosteroids: Less commonly used now due to side effects, but may be considered in specific cases.
• Laser therapy: Can be used to treat residual redness or telangiectasias (small dilated blood vessels) after the hemangioma has involuted, or for ulcerated lesions.
• Surgery: Reserved for cases where the hemangioma causes significant cosmetic deformity, functional impairment, or fails to respond to medical therapy, especially after involution is complete.

The decision for treatment is individualized and made in consultation with a healthcare professional, often involving a multidisciplinary team of pediatricians, dermatologists, and other specialists.